Australia markets closed

Cellectis S.A. (CMVLF)

Other OTC - Other OTC Delayed price. Currency in USD
Add to watchlist
7.03-0.01 (-0.14%)
At close: 01:23PM EST
Full screen
Trade prices are not sourced from all markets
Previous close7.04
Open7.04
Bid0.00 x 0
Ask0.00 x 0
Day's range7.03 - 7.04
52-week range7.03 - 33.48
Volume200
Avg. volume329
Market cap326.634M
Beta (5Y monthly)2.19
PE ratio (TTM)N/A
EPS (TTM)-2.92
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    Monthly information on share capital and company voting rights

    (Article 223-16 of General Regulation of the French financial markets authority)NEW YORK, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Listing market: Euronext Growth ISIN code: FR0010425595 DateTotal number of shares in the capitalTotal number of voting rights12/31/202145,484,81051,085,782 About Cellectis Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunoth

  • Zacks

    Allogene (ALLO) Clinical Hold on CAR-T Studies Removed by FDA

    The FDA removes the hold on Allogene's (ALLO) clinical studies evaluating AlloCAR T therapy candidates after investigations confirmed that there is no chromosomal abnormality in its candidates.

  • GlobeNewswire

    Cellectis’ Licensed Partner, Allogene Therapeutics, Announces Removal of FDA Clinical Hold on their Clinical Trials

    • Allogene reported that Chromosomal Abnormality Was Not the Result of TALEN® Gene Editing or Allogene’s Manufacturing Process • Allogene to Initiate a Phase 2 Pivotal Clinical Trial of ALLO-501A in Relapsed/Refractory Large B-cell Lymphoma Mid-year 2022 Pending FDA Discussion NEW YORK, Jan. 10, 2022 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS - Nasdaq: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapie